Sydney IVF: Stem Cell Research Case Solution And Analysis, HBR Case Study Solution & Analysis of Harvard Case Studies

This case describes the implementation of policies and decisions on risk management in Sydney IVF research in vitro fertilization and stem cell company based in Australia. Doctor. Robert Jansen and Jock Anderson, who was one of the founders of Sydney IVF in 1986, has developed a new technology that they leverage to cut the lead in risky artificial insemination business. As the company grew, its leaders have grappled with the management of the political, ethical and business risks related to the controversial laboratory-based fertility of fields, the introduction of sophisticated safeguards, such as an independent ethics committee and the "whistle blower" system for employees associated with the practice of the company. In less than two decades, Sydney IVF has grown from just four employees in more than 200, expanded internationally, and has expanded its services to include prenatal screening for genetic diseases and DNA tests to determine the origin and paternity. In addition, the company launched a subsidiary Stem Cell. CEO Robert Jansen hopes to grow company Stem Cell, but faces many challenges, including significant ethical risks, complex regulatory environment, and an uncertain future for stem cells. The case describes how Jansen safeguards against risk without stifling innovative spirit necessary for the commercialization of stem cells. "Hide
by Robert L. Simons, Kathryn Rosenberg, Natalie Kindred Source: Harvard Business School 22 pages. Publication Date: January 26, 2009. Prod. #: 109017-PDF-ENG